NEW YORK (GenomeWeb News) – Illumina said this week that its board has authorized the repurchase of up to $250 million of the company's common stock. The new repurchase program is in addition to Illumina's current program, which has $117.5 million available for share repurchases.


The US Food and Drug Administration confirmed by notice in the Federal Register that its Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will review Exact Sciences' premarket approval application for the Cologuard colorectal screening test on March 27.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.